Statins and the Brain: More than Lipid Lowering Agents?

ABSTRACT:

Background

Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions.

Objective

The purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statin

SUBMITTER: Fracassi A 

PROVIDER: S-EPMC6341496 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature